Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Medtronic
Express Scripts
QuintilesIMS
Moodys
Chubb
Fuji
Colorcon

Generated: June 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,338,489

« Back to Dashboard

Summary for Patent: 8,338,489
Title:Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Abstract: The present disclosure relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present disclosure provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.
Inventor(s): Leaute-Labreze; Christine (Le Haillan, FR), Dumas De La Roque; Eric (Villenave d'Ornon, FR), Taieb; Alain (Bordeaux, FR), Thambo; Jean-Beno t (Bordeaux, FR)
Assignee: Universite Victor Segalen--Bordeaux 2 (Bordeaux Cedex, FR)
Application Number:12/599,266
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;

Drugs Protected by US Patent 8,338,489

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pierre Fabre Derma HEMANGEOL propranolol hydrochloride SOLUTION;ORAL 205410-001 Mar 14, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD TO TREAT HEMANGIOMA. ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,338,489

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
07291273Oct 19, 2007
PCT Information
PCT FiledOctober 16, 2008PCT Application Number:PCT/IB2008/002746
PCT Publication Date:April 23, 2009PCT Publication Number: WO2009/050567

Non-Orange Book US Patents Family Members for Patent 8,338,489

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,987,262 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas ➤ Try a Free Trial
9,173,858 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,338,489

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 068927 ➤ Try a Free Trial
Austria 512661 ➤ Try a Free Trial
Australia 2008313405 ➤ Try a Free Trial
Brazil PI0816536 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Federal Trade Commission
Daiichi Sankyo
Argus Health
Merck
US Army
Boehringer Ingelheim
Fuji
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.